IPHA vs. SIGA, OLMA, KROS, BCAX, KALV, GOSS, SNDL, SVRA, ARVN, and MBX
Should you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Siga Technologies (SIGA), Olema Pharmaceuticals (OLMA), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), KalVista Pharmaceuticals (KALV), Gossamer Bio (GOSS), SNDL (SNDL), Savara (SVRA), Arvinas (ARVN), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.
Innate Pharma vs. Its Competitors
Innate Pharma (NASDAQ:IPHA) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.
In the previous week, Siga Technologies had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Siga Technologies and 1 mentions for Innate Pharma. Siga Technologies' average media sentiment score of 1.00 beat Innate Pharma's score of 0.00 indicating that Siga Technologies is being referred to more favorably in the news media.
Siga Technologies has a net margin of 45.73% compared to Innate Pharma's net margin of 0.00%. Siga Technologies' return on equity of 40.52% beat Innate Pharma's return on equity.
Siga Technologies has higher revenue and earnings than Innate Pharma.
Innate Pharma has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.
Innate Pharma presently has a consensus price target of $6.50, suggesting a potential upside of 215.53%. Given Innate Pharma's higher probable upside, research analysts plainly believe Innate Pharma is more favorable than Siga Technologies.
0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 2.0% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Siga Technologies beats Innate Pharma on 9 of the 13 factors compared between the two stocks.
Get Innate Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innate Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:IPHA) was last updated on 10/3/2025 by MarketBeat.com Staff
Free IPHA Stock Alerts